Protocol to identify novel immunotherapy biomarkers based on transcriptomic data in human cancers
Jie Mei(Sun Yat-sen University), Yongmei Yin(Nanjing Medical University), Wenjun Mao(Wuxi People's Hospital), Yichao Zhu(Nanjing Medical University), Junying Xu(Wuxi People's Hospital), Yan Zhang(Nanjing Medical University), Xinyuan Zhao(Qinghai University), Rui Xu(Jiangsu Province Hospital), Yun Cai(Jiangsu University)
Cited by 17
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
The role of lipid metabolic reprogramming in tumor microenvironment
|Theranostics|2023|223
Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma
|Cancer Discovery|2022|137